Labiotech.eu

More News! 31 Oct 2022

Drug discovery company signs exclusive license to use university’s technology

A drug discovery and development company using deubiquitylase (DUB) modulators as therapeutics for areas of high unmet needs has signed an exclusive license with the University of Southern Denmark for its UbiSite technology. Sheelagh Frame, is chief scientific officer, at Ubiquigent, the company that has signed the agreement. She said: “We are delighted to have […]

October 31, 2022 - 3 minutesmins - By Liza Laws

News and Trends 31 Oct 2022

Replay Bio launches HSV gene therapy company to target retinal eye disease

Replay Bio has announced the launch of Eudora, an HSV (herpes simplex virus) gene therapy company targeting genetic retinal diseases. It is the first of Replay’s product companies to leverage its high payload capacity HSV delivery vector, synHSV. Eudora’s co-founders Joe Glorioso, Mark Blumenkranz, David Schaffer, and Vinit Mahajan, are entrepreneurs who have worked in […]

October 31, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 31 Oct 2022

Scientists say RNA production inhibitors important in cancer research

A study by researchers at the Biomedical Institute of Seville (IBIS) and the University of Seville, in collaboration with the Danish Cancer Society, shows that inhibiting RNA synthesis after radiation therapy facilitates the death of tumor cells. The study was published in the journal Nature Communications. RNA has been shown to be essential for repairing […]

October 31, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Oct 2022

Startup BioRaptor raises $3M to drive AI insights for scientists

BioRaptor has raised $3M in funding, which it says will allow it to put the power of AI-generated insights into the hands of every scientist. The round was led by lool Ventures and CPT Capital and was joined by FoodHack and other strategic angel investors. BioRaptor is building an operating system for biology research and […]

October 31, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Oct 2022

PhoreMost and Arvinas to collaborate on drug discovery against multiple therapeutic targets

U.K. biopharma company PhoreMost Ltd. has entered into a multi-target collaboration with Arvinas, a company active in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will receive research funding and will be eligible for pre-clinical, clinical, and commercial milestones. PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. […]

October 31, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Oct 2022

Reprogramming immune cells can fight melanoma

A new way of reprogramming immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard-to-treat skin cancer, melanoma. The University of Bristol, in the U.K. led the discovery, which has been published in Advanced Science. It demonstrates a new way to clear early stage pre-cancerous and even […]

October 31, 2022 - 3 minutesmins - By Jim Cornall

longevity treatment bioAge Kristen Fortney

Interview 31 Oct 2022

AI and biobanks could open the way to longevity treatments

The development of longevity treatments is hampered by a lack of biomarkers and validated drug targets. BioAge’s co-founder and CEO, Kristen Fortney, explains how the firm is enlisting machine learning (ML), artificial intelligence (AI) and biobanks to fill in the gaps. The quest for human longevity treatments is attracting big cash in the biotech industry. […]

October 31, 2022 - 7 minutesmins - By Jonathan Smith

Interview 28 Oct 2022

Migraines: a new vaccine frontier beyond infectious diseases

By bringing the efficiency and affordability of vaccines to chronic diseases such as migraines, U.S. company Vaxxinity aims to open a new frontier for vaccines in an effort to reach all patient populations, regardless of location or income. Migraine causes severe headaches that are characterized by throbbing pain and associated symptoms such as sensitivity to […]

October 28, 2022 - 7 minutesmins - By Omnia Ibrahim

elypta renal cell carcinoma kidney cancer

News and Trends 28 Oct 2022

Rila Therapeutics exits stealth mode to address renal fibrosis

Rila Therapeutics, a biotherapeutics company focused on addressing the critical unmet medical needs to treat renal fibrosis, has emerged from stealth mode. Rila Therapeutics has identified a promising, first-in-class allosteric small molecule targeting HIPK2 to inhibit kidney fibrosis. The breakthrough discovery aiming to advance the treatment of renal disease was developed in collaboration with Mount […]

October 28, 2022 - 3 minutesmins - By Jim Cornall

More News! 28 Oct 2022

‘Dark matter’ creates a whole new level of cancer gene activity in tumors, researchers say

A whole new level of control of cancer gene activity within tumors, has been described by researchers as ‘dark matter’. It was recently discovered and published in two major studies at the same time in Nature that cancers can evolve to become more aggressive without relying on DNA mutations. Testing cancers for just the DNA […]

October 28, 2022 - 6 minutesmins - By Liza Laws

Persephone Bisociences Microbiome health

Startup Scout 28 Oct 2022

Persephone Biosciences studies the microbiome in baby poop

Disruption in the gut microbiome is linked to a wide range of health problems in newborn babies and patients with cancer. Persephone Biosciences is studying stool samples from these populations to devise bacterial treatments that improve gut health. Research into the gut microbiome has advanced a long way in the last decades. One major boost […]

October 28, 2022 - 6 minutesmins - By Jonathan Smith

AKT inhibitor ipatasertib shows signs of effectiveness in patient trial

News and Trends 28 Oct 2022

AKT inhibitor shows signs of effectiveness in patient trial

In a trial matching new treatments to cancer patients based on the genetic make-up of their tumors, 22% of the patients treated with the AKT inhibitor drug ipatasertib had their tumors shrink. This included patients with breast cancer and endometrial cancer as well as two rarer forms – anal and salivary gland. In the majority […]

October 28, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Drug discovery company signs exclusive license to use university’s technology

Replay Bio launches HSV gene therapy company to target retinal eye disease

Scientists say RNA production inhibitors important in cancer research

Startup BioRaptor raises $3M to drive AI insights for scientists

PhoreMost and Arvinas to collaborate on drug discovery against multiple therapeutic targets

Reprogramming immune cells can fight melanoma

AI and biobanks could open the way to longevity treatments

Migraines: a new vaccine frontier beyond infectious diseases

Rila Therapeutics exits stealth mode to address renal fibrosis

‘Dark matter’ creates a whole new level of cancer gene activity in tumors, researchers say

Persephone Biosciences studies the microbiome in baby poop

AKT inhibitor shows signs of effectiveness in patient trial

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!